Clicky

Algernon Pharmaceuticals Inc.(AGNPF)

Description: Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, focuses in the areas of non?alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19 in Canada and Australia. The company's lead candidate is NP-120, an N-methyl-d-aspartate (NMDA) receptor glutamate receptor antagonist, which targets NMDA-type subunit 2B (Glu2NB), as well as exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. It is also developing AP-188 (N,N-Dimethyltryptamine), a psychedelic compound that is part of the tryptamine family for the treatment of ischemic stroke in humans. Algernon Pharmaceuticals Inc. is headquartered in Vancouver, Canada.


Keywords: Chronic Kidney Disease Inflammatory Bowel Disease Idiopathic Pulmonary Fibrosis Ischemic Stroke Glutamate Acute Lung Injury Neurotransmitters Chronic Cough Dicarboxylic Acids N Methyl D Aspartic Acid Glutamate Neurotransmitter) Ionotropic Glutamate Receptors

Home Page: algernonpharmaceuticals.com

700 West Pender Street
Vancouver, BC V6C 1G8
Canada
Phone: 604 398 4175


Officers

Name Title
Mr. Christopher J. Moreau CEO & Director
Dr. Christopher Bryan Ph.D. VP of Research & Operations
Mr. James F. Kinley C.A., CPA Chief Financial Officer

Exchange: OTCQB

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.0175
Price-to-Sales TTM: 0
IPO Date:
Fiscal Year End: August
Full Time Employees: 0
Back to stocks